Product
QL1209
1 clinical trial
1 indication
Indication
Breast CancerClinical trial
A Randomized, Multicenter, Double-Blind, Parallel-Controlled, Phase III Clinical Study to Evaluate QL1209/Pertuzumab in Combination With Docetaxel in Patients With Early-Stage or Locally Advanced HER2-Positive and ER/PR-negative Breast Cancer.Status: Completed, Estimated PCD: 2022-08-22